Results of univariate and multivariate analysis of overall survival among 738 patients with Ph+ ALL
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR (95% Cl) . | P . | RR (95% Cl) . | P . | |
| Imatinib use before SCT | ||||
| No | 1 (Reference) | 1 (Reference) | ||
| Yes | 0.56 (0.45-0.70) | <.001 | 0.57 (0.42-0.77) | <.001 |
| Age at SCT (regression) | 1.02 (1.01 −1.03) | .002 | 1.02 (1.01-1.03) | <.001 |
| HLA disparity | ||||
| Matched | 1 (Reference) | 1 (Reference) | ||
| Mismatched | 0.89 (0.71-1.11) | .30 | 0.89 (0.66-1.20) | .430 |
| Stem cell source | ||||
| Related bone marrow | 1 (Reference) | 1 (Reference) | ||
| Unrelated bone marrow | 0.81 (0.62-1.10) | .13 | 0.92 (0.63-1.33) | .640 |
| Related peripheral blood | 1.08 (0.79-1.48) | .64 | 1.27 (0.90-1.78) | .180 |
| Cord blood | 0.86 (0.61-1.22) | .39 | 1.25 (0.78-2.0) | .360 |
| PS at SCT | ||||
| 0 | 1 (Reference) | .24 | 1 (Reference) | |
| 1-4 | 1.15 (0.91-1.47) | 1.05 (0.82-1.36) | .690 | |
| Duration from diagnosis to SCT | ||||
| >180 days | 1 (Reference) | 1 (Reference) | ||
| ≤180 days | 1.26 (1.02-1.57) | .03 | 1.31 (1.03-1.67) | .030 |
| BCR-ABL subtype | ||||
| Major | 1 (Reference) | 1 (Reference) | ||
| Minor | 0.77 (0.36-1.66) | .51 | NA | |
| Major and minor | 0.90 (0.44-1.83) | .78 | ||
| Donor recipient gender match | ||||
| Male-male | 1 (Reference) | 1 (Reference) | ||
| Male-female | 0.83 (0.61-1.11) | .21 | 0.78 (0.57-1.06) | .110 |
| Female-male | 0.78 (0.56-1.08) | .13 | 0.77 (0.55-1.07) | .120 |
| Female-female | 0.71 (0.51-0.98) | .03 | 0.70 (0.50-0.98) | .040 |
| Conditioning regimen | ||||
| Reduced intensity | 1 (Reference) | 1 (Reference) | ||
| Myeloabrative | 0.96 (0.60-1.53) | .87 | 1.04 (0.64-1.70) | .150 |
| WBC at diagnosis | ||||
| <30 000/μL | 1 (Reference) | 1 (Reference) | ||
| ≤30 000/μL | 1.29 (1.04-1.61) | .02 | 1.07 (0.99-1.14) | .053 |
| GVHD prophylaxis | ||||
| CyA/MTX | 1 (Reference) | 1 (Reference) | ||
| Tacrorimus/MTX | 0.78 (0.62-0.98) | .03 | 0.98 (0.73-1.31) | .899 |
| Cytogenetics | ||||
| t(9;22)only | 1 (Reference) | 1 (Reference) | ||
| Other abnormality | 0.97 (0.71-1.34) | .87 | NA | |
| ABO blood type disparity | ||||
| Match | 1 (Reference) | 1 (Reference) | ||
| Minor | 1.12 (0.83-1.51) | .48 | NA | |
| Major | 1.21 (0.93-1.59) | .16 | NA | |
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR (95% Cl) . | P . | RR (95% Cl) . | P . | |
| Imatinib use before SCT | ||||
| No | 1 (Reference) | 1 (Reference) | ||
| Yes | 0.56 (0.45-0.70) | <.001 | 0.57 (0.42-0.77) | <.001 |
| Age at SCT (regression) | 1.02 (1.01 −1.03) | .002 | 1.02 (1.01-1.03) | <.001 |
| HLA disparity | ||||
| Matched | 1 (Reference) | 1 (Reference) | ||
| Mismatched | 0.89 (0.71-1.11) | .30 | 0.89 (0.66-1.20) | .430 |
| Stem cell source | ||||
| Related bone marrow | 1 (Reference) | 1 (Reference) | ||
| Unrelated bone marrow | 0.81 (0.62-1.10) | .13 | 0.92 (0.63-1.33) | .640 |
| Related peripheral blood | 1.08 (0.79-1.48) | .64 | 1.27 (0.90-1.78) | .180 |
| Cord blood | 0.86 (0.61-1.22) | .39 | 1.25 (0.78-2.0) | .360 |
| PS at SCT | ||||
| 0 | 1 (Reference) | .24 | 1 (Reference) | |
| 1-4 | 1.15 (0.91-1.47) | 1.05 (0.82-1.36) | .690 | |
| Duration from diagnosis to SCT | ||||
| >180 days | 1 (Reference) | 1 (Reference) | ||
| ≤180 days | 1.26 (1.02-1.57) | .03 | 1.31 (1.03-1.67) | .030 |
| BCR-ABL subtype | ||||
| Major | 1 (Reference) | 1 (Reference) | ||
| Minor | 0.77 (0.36-1.66) | .51 | NA | |
| Major and minor | 0.90 (0.44-1.83) | .78 | ||
| Donor recipient gender match | ||||
| Male-male | 1 (Reference) | 1 (Reference) | ||
| Male-female | 0.83 (0.61-1.11) | .21 | 0.78 (0.57-1.06) | .110 |
| Female-male | 0.78 (0.56-1.08) | .13 | 0.77 (0.55-1.07) | .120 |
| Female-female | 0.71 (0.51-0.98) | .03 | 0.70 (0.50-0.98) | .040 |
| Conditioning regimen | ||||
| Reduced intensity | 1 (Reference) | 1 (Reference) | ||
| Myeloabrative | 0.96 (0.60-1.53) | .87 | 1.04 (0.64-1.70) | .150 |
| WBC at diagnosis | ||||
| <30 000/μL | 1 (Reference) | 1 (Reference) | ||
| ≤30 000/μL | 1.29 (1.04-1.61) | .02 | 1.07 (0.99-1.14) | .053 |
| GVHD prophylaxis | ||||
| CyA/MTX | 1 (Reference) | 1 (Reference) | ||
| Tacrorimus/MTX | 0.78 (0.62-0.98) | .03 | 0.98 (0.73-1.31) | .899 |
| Cytogenetics | ||||
| t(9;22)only | 1 (Reference) | 1 (Reference) | ||
| Other abnormality | 0.97 (0.71-1.34) | .87 | NA | |
| ABO blood type disparity | ||||
| Match | 1 (Reference) | 1 (Reference) | ||
| Minor | 1.12 (0.83-1.51) | .48 | NA | |
| Major | 1.21 (0.93-1.59) | .16 | NA | |
CyA, cyclospoline; NA, not applicable; RR, relative risk.